Joseph John to Bacteremia
This is a "connection" page, showing publications Joseph John has written about Bacteremia.
Connection Strength
0.078
-
Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006 Aug; 50(8):2751-5.
Score: 0.056
-
Relatedness of strains of methicillin-resistant coagulase-negative Staphylococcus colonizing hospital personnel and producing bacteremias in a neonatal intensive care unit. Pediatr Infect Dis J. 1992 Nov; 11(11):935-40.
Score: 0.022